“Having three FDA-approved therapies for patients with chronic GVHD [cGVHD], a debilitating condition, is truly remarkable, given that just over five years ago there was not a single FDA-approved therapy available to these patients,” said Amin M. Alousi, MD, the director of the GVHD Clinic and Research Program, and a professor of stem cell transplantation at The University of Texas MD Anderson Cancer Center, in Houston.
Ruxolitinib (Jakafi, Incyte) received an indication in September